Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Blaine Montague

Physician Assistant Spanish Fork, UT Physician Assistant

NPI 1366811606 CMS profile 10588253

819 E Marketplace Drive, Spanish Fork, UT 84660

Open in the dashboard

General payments

$1,224

35 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Blaine Montague of Spanish Fork, UT is reported in the CMS Open Payments database as having received $1,224 across 35 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $190 7
2024 General $153 7
2023 General $151 8
2022 General $678 11
2021 General $52 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Blaine Montague
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Blaine Montague were reported at $190. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Blaine Montague Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $52 $132 $37–$438 $132
2022 $678 $155 $48–$522 $149
2023 $151 $167 $52–$557 $160
2024 $153 $178 $55–$600 $164
2025 $190 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Stryker Corporation $748 15 payments
  2. Zimmer Biomet Holdings, Inc. $358 16 payments
  3. DePuy Synthes Sales Inc. $68 2 payments
  4. Catalyst OrthoScience $31 1 payment
  5. Innovation Technologies Inc $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $828 32 payments
  2. Travel and Lodging $396 3 payments
Products named General payments · program years 2021–2025
  1. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $396 3 payments
  2. AEQUALIS PERFORM $216 4 payments
  3. MAKO $115 7 payments
  4. VA-LCP $68 2 payments
  5. Comprehensive Shoulder System $64 3 payments
  6. Sidus Stem-Free Shoulder $43 2 payments
  7. Juggerknotless Soft Anchor $41 2 payments
  8. NA Trauma $41 1 payment
  9. NA Orthopedics $41 1 payment
  10. Tricera Handpiece $40 2 payments
  11. Other $189 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

364

Median for Physician Assistant: 241

Drug cost

$4,475

Median for Physician Assistant: $4,110

Branded share of claims

4.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 66 $1,499
Naloxone Hcl Generic 18 $1,133
Oxycodone Hcl Generic 99 $730
Tramadol Hcl Generic 123 $698
Hydromorphone Hcl Generic 29 $171
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 18 $156
Ondansetron Hcl Generic 11 $86

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$39,079

Of which drugs: $9,942

Medicare patients

165

Average age 74

Services billed

6,755

96 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Ischemic heart disease 21%
Depression 21%
Diabetes 20%
Chronic kidney disease 17%
Osteoporosis 16%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 19 71 $6,572
Injection, methylprednisolone acetate, 1 mg J1010 Office 51 5,640 $571
Injection, methylprednisolone acetate, 40 mg J1030 Office 19 51 $159

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

35 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record